By admin | Published:
August 29, 2009
Carlton Evans
Carlton Evans of the London School of Hygiene and Tropical Medicine explains to Peter Goodwin how his research project, supported by the UK Department for International Development (DFID), has succeeded in reducing risk factors for TB in households living on less than a dollar a day in the Ventanilla district of Lima, Peru. A microfinance scheme—providing small loans to help people use their skills to earn a living—has resulted in big reductions of adverse factors associated with causing tuberculosis.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 28, 2009
Delia Boccia
Delia Boccia of the London School of Hygiene and Tropical Medicine tells Peter Goodwin about her research findings in Zambia which have revealed that the factor within impoverised communities which has the strongest link with TB infection is poor nutrition. She explains what should be the priorities for improving nutrition as a powerful means of cutting rates of TB.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 17, 2009
Ruth McNerney
With a growing threat from tuberculosis around the world—made worse by the spread of HIV/AIDS—there is an urgent need for new diagnostic tests for TB which are more appropriate for use in communities and small clinics rather than big hospitals. Peter Goodwin interviewed Ruth McNerney of the London School of Hygiene and Tropical Medicine, organiser of a symposium on “Point-of-Care” tests for TB, held in the city of Porto, Portugal during the annual meeting of the European Society of Mycobacteriology (July 5-8, 2009).
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 8, 2009
Éveline Boucher
BARCELONA, SPAIN—Adding cetuximab to gemcitabine/oxaliplatin (GEMOX) chemotherapy controlled disease among two thirds of patients with advanced biliary cancer in a trial reported at the World Congress on Gastrointestinal Cancer. Éveline Boucher from the Centre Eugene Marquis, in Rennes, France, presented preliminary findings from a phase II open-label study among 101 patients who had not already received palliative treatment for their advanced biliary cancers, and had WHO performance status 0-1.
She discussed her team’s findings with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
August 5, 2009
Michel Ducreux
Adding the oral drug capecitabine to a regimen of bevacizumab plus irinotecan was as effective as adding infusions of 5FU/folinic acid for patients who had metastatic colorectal cancer in a phase II study presented to the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; Abstract: 0-0013). Michel Ducreux, Head of the Gastrointestinal Service at the Institut Gustave Roussy in Villejuif, Paris, discussed the new evidence and its clinical implications with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.